Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Oral Cleft Prevention Program
This study is currently recruiting participants.
Verified by National Institute of Dental and Craniofacial Research (NIDCR), July 2008
Sponsors and Collaborators: National Institute of Dental and Craniofacial Research (NIDCR)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
University of Iowa
RTI International
University of Sao Paulo
Information provided by: National Institute of Dental and Craniofacial Research (NIDCR)
ClinicalTrials.gov Identifier: NCT00397917
  Purpose

The purpose of this study is to asses if taking 4 mg of folic acid per day at preconception and during the first three months of pregnancy decreases the risk of having a child with cleft lip and palate compared to 0.4 mg folic acid for women who have an oral cleft or have had previously child with an oral cleft.


Condition Intervention Phase
Cleft Lip
Cleft Palate
Drug: Folic acid: 4 mg versus 0.4 mg per day
Phase III

Genetics Home Reference related topics: Baller-Gerold syndrome Crouzon syndrome
MedlinePlus related topics: Cleft Lip and Palate
Drug Information available for: Folic acid
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Dose Comparison, Parallel Assignment, Efficacy Study
Official Title: Oral Cleft Prevention Program

Further study details as provided by National Institute of Dental and Craniofacial Research (NIDCR):

Primary Outcome Measures:
  • Recurrence of cleft lip and palate [ Time Frame: 3 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 6000
Study Start Date: November 2006
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Folic acid: 4 mg versus 0.4 mg per day
    Folic acid
Detailed Description:

Cleft lip and palate is a common and burdensome birth defect that has large health ramifications and requires surgical, speech, behavioral, dental, and medical interventions. There is some evidence suggesting that taking folic acid particularly at large doses during preconception and first trimester of pregnancy may decrease the risk of oral cleft recurrence, which is the risk of having a child with an oral cleft for women who have an oral cleft or who have had a child with a cleft. However this evidence is based on study designs that are incapable of contributing the preventive effects to folic acid with adequate confidence, and the real effect of folic acid on cleft recurrence prevention remains to be identified. Taking 4 mg of folic acid per day at preconception and first trimester of pregnancy has also been shown to prevent the recurrence of neural tube defects by up to 70%, providing further support to evaluate this intervention for oral cleft recurrence.

This study evaluates the effects of supplementation with 4 versus 0.4 mg of folic acid per day at preconception and during the first three months of pregnancy on recurrence of cleft lip and palate. Up to 6000 women will be randomly assigned to 4 versus 0.4 mg groups. The primary aim is to compare the recurrence rates in the offspring of trial mothers in the two groups. Secondary aims are to compare the two groups on several outcomes including miscarriage, twinning, pre-eclampsia, serum and red cell folate levels, severity of oral clefts and occurrence of other birth defects in the offspring of trial mothers, and birth weight and gestational age of trial babies, and to compare the recurrence in the two groups to that in historic controls.

  Eligibility

Ages Eligible for Study:   16 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women with cleft lip with/out palate (CLP), 16 to 45 years of age registered at the study clinics in Brazil or Women (16 to 45 years of age) with at least one natural child of any age with CLP registered at the study clinics.
  • Women must reside in the catchment area of the study, which includes the states where the study clinics are located and surrounding states.

Exclusion Criteria:

  • Consanguineous couples (up to third degree, i.e. first cousins or closer).
  • Pregnany at the time of recruitment. Women will be recontacted later at an appropriate time for participation in the study.
  • Couples either one of which have been sterilized.
  • Taking any form of seizure medication.
  • Planning to move outside of the study catchment area within the next year.
  • B12 deficiency (<174 pg/mL or 129.15 pmol/L).
  • Being allergic to folic acid.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00397917

Contacts
Contact: Jeff Murray, MD 319-335-6897 jeff-murray@uiowa.edu
Contact: Danilo Moretti-Ferreira, MD 55-142355-8183 danilo@ibb.unesp.br

Locations
United States, Iowa
University of Iowa Recruiting
Iowa City, Iowa, United States, 52242
Contact: Jeff C Murray, MD     319-335-6897     jeff-murray@uiowa.edu    
Principal Investigator: Jeff Murray, MD            
Sponsors and Collaborators
University of Iowa
RTI International
University of Sao Paulo
Investigators
Principal Investigator: Jeffrey Murray, MD University of Iowa
  More Information

Responsible Party: University of Iowa ( Jeff Murray, MD )
Study ID Numbers: NIDCR-17958
Study First Received: November 8, 2006
Last Updated: July 17, 2008
ClinicalTrials.gov Identifier: NCT00397917  
Health Authority: United States: Federal Government

Study placed in the following topic categories:
Folic Acid
Mouth Diseases
Cleft Palate
Musculoskeletal Diseases
Cleft Lip
Craniofacial Abnormalities
Maxillofacial Abnormalities
Stomatognathic Diseases
Congenital Abnormalities
Musculoskeletal Abnormalities

Additional relevant MeSH terms:
Vitamin B Complex
Hematinics
Growth Substances
Physiological Effects of Drugs
Hematologic Agents
Jaw Diseases
Stomatognathic System Abnormalities
Lip Diseases
Pharmacologic Actions
Mouth Abnormalities
Therapeutic Uses
Vitamins
Jaw Abnormalities
Micronutrients

ClinicalTrials.gov processed this record on January 14, 2009